Table 2.
Baseline characteristics of patients according to PCSK9 stratification
| Variables | Total (n = 1225) | PCSK9 concentration (ng/mL) | p value | |
|---|---|---|---|---|
| < 234.52 (n = 612) | ≥ 234.52 (n = 613) | |||
| Clinical characteristics | ||||
| Age (years) | 57.8 ± 10.1 | 57.1 ± 10.1 | 58.4 ± 10.0 | 0.027 |
| Male sex | 833 (68.0) | 469 (76.6) | 364 (59.4) | < 0.001 |
| BMI (kg/m2) | 25.9 ± 3.3 | 26.0 ± 3.5 | 25.8 ± 3.2 | 0.217 |
| Hypertension | 854 (69.7) | 424 (69.3) | 430 (70.1) | 0.742 |
| Family history of CAD | 289 (23.6) | 126 (20.6) | 163 (26.6) | 0.013 |
| Diabetes mellites | 377 (30.8) | 180 (29.4) | 197 (32.1) | 0.301 |
| Current smoker | 481 (39.3) | 258 (53.6) | 223 (46.4) | 0.038 |
| Drinking | 284 (23.2) | 159 (56.0) | 125 (44.0) | 0.020 |
| Laboratory parameters | ||||
| FPG (mmol/L) | 5.9 ± 1.9 | 5.7 ± 1.7 | 6.0 ± 2.1 | 0.012 |
| HbA1C (%) | 6.2 ± 1.1 | 6.1 ± 1.0 | 6.3 ± 1.2 | 0.010 |
| ALT(U/L) | 20 (15,29) | 20 (15,28) | 20 (14,30) | 0.769 |
| Creatinine (μmol/L) | 77.7 ± 17.5 | 77.9 ± 16.1 | 77.5 ± 18.8 | 0.680 |
| TC (mmol/L) | 4.82 ± 0.96 | 4.67 ± 0.90 | 4.98 ± 0.99 | < 0.001 |
| TG (mmol/L) | 1.61 (1.16,2.31) | 1.55 (1.12,2.30) | 1.65 (1.20,2.34) | 0.226 |
| HDL-C (mmol/L) | 1.09 ± 0.32 | 1.07 ± 0.33 | 1.12 ± 0.32 | 0.011 |
| LDL-C (mmol/L) | 3.15 ± 0.85 | 3.00 ± 0.78 | 3.29 ± 0.89 | < 0.001 |
| Fibrinogen (μg/mL) | 3.1 ± 0.8 | 3.0 ± 0.6 | 3.2 ± 0.8 | < 0.001 |
| NT-proBNP (pg/mL) | 51.9 (31.0,109.3) | 49.45 (31.2,92.5) | 53.2 (30.4,130.0) | 0.083 |
| Diseased vessels | ||||
| One vessel | 438 (35.8) | 241 (39.4) | 197 (32.1) | |
| Two vessels | 365 (29.8) | 173 (28.2) | 192 (31.3) | |
| Three vessels | 422 (34.4) | 198 (32.4) | 224 (36.5) | |
| LVEF (%) | 64.7 ± 6.7 | 64.6 ± 6.9 | 64.8 ± 6.6 | 0.716 |
| Gensini score | 27 (11,44) | 25 (10,43) | 28 (12,44) | 0.095 |
| Medications | ||||
| Aspirin | 464 (37.9) | 228 (37.3) | 236 (38.5) | 0.654 |
| Clopidogrel | 130 (10.6) | 61 (10.0) | 69 (11.3) | 0.464 |
| ACEI/ARB | 252 (20.6) | 119 (19.4) | 133 (21.7) | 0.330 |
| β-blockers | 238 (19.4) | 108 (17.6) | 130 (21.2) | 0.115 |
| MACEs | 103 (8.4) | 36 (5.9) | 67 (10.9) | 0.001 |
PCSK9 proprotein convertase subtilisin/kexin type 9, BMI body mass index, CAD coronary artery disease, FPG fasting plasma glucose, HbA1C hemoglobin A1C, ALT alanine aminotransferase, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NT-proBNP N-Terminal pro-brain natriuretic peptide, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, MACEs major adverse cardiovascular events, p < 0.05 suggests significant difference